# A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

> clinical trial · VERIFIED · 2026-08-21

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Small Cell Lung Cancer Extensive Stage

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07227597

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.